201 related articles for article (PubMed ID: 36943467)
1. Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome.
Biró E; Erdélyi D; Varga P; Sinkó M; Bartyik K; Kovács G; Ottóffy G; Vincze F; Szegedi I; Kiss C; Szabó T
Pediatr Nephrol; 2023 Sep; 38(9):3117-3127. PubMed ID: 36943467
[TBL] [Abstract][Full Text] [Related]
2. Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome.
Lemerle M; Schmidt A; Thepot-Seegers V; Kouatchet A; Moal V; Raimbault M; Orvain C; Augusto JF; Demiselle J
J Nephrol; 2022 Jul; 35(6):1627-1636. PubMed ID: 35107777
[TBL] [Abstract][Full Text] [Related]
3. Fluid overload and acute kidney injury in children with tumor lysis syndrome.
Flood K; Rozmus J; Skippen P; Matsell DG; Mammen C
Pediatr Blood Cancer; 2021 Dec; 68(12):e29255. PubMed ID: 34302706
[TBL] [Abstract][Full Text] [Related]
4. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
5. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
[TBL] [Abstract][Full Text] [Related]
6. Laboratory and clinical features of tumor lysis syndrome in children with non-Hodgkin lymphoma and evaluation of long-term renal functions in survivors.
Bozkurt S; Genc DB; Vural S
BMC Pediatr; 2024 Jan; 24(1):85. PubMed ID: 38297237
[TBL] [Abstract][Full Text] [Related]
7. Hydration effect on kidney function and serum electrolyte in children with tumor lysis syndrome (TLS) and risk of TLS.
Yulistiani ; Tiffany C; Ugrasena IDG; Qibtiyah M
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):603-609. PubMed ID: 34214307
[TBL] [Abstract][Full Text] [Related]
8. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.
Matuszkiewicz-Rowinska J; Malyszko J
Kidney Blood Press Res; 2020; 45(5):645-660. PubMed ID: 32998135
[TBL] [Abstract][Full Text] [Related]
9. Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies.
Anderson A; Shoulders L; James V; Ashcraft E; Cheng C; Ribeiro R; Elbahlawan L
Front Oncol; 2023; 13():1234677. PubMed ID: 37664024
[TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
Patel V; Case R
J Investig Med High Impact Case Rep; 2020; 8():2324709620944709. PubMed ID: 32720820
[TBL] [Abstract][Full Text] [Related]
12. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia.
Kedar A; Grow W; Neiberger RE
Pediatr Hematol Oncol; 1995; 12(2):129-34. PubMed ID: 7626380
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
14. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Canet E; Cheminant M; Zafrani L; Thieblemont C; Galicier L; Lengline E; Schnell D; Reuter D; Darmon M; Schlemmer B; Azoulay E
Leuk Lymphoma; 2014 Oct; 55(10):2362-7. PubMed ID: 24325633
[TBL] [Abstract][Full Text] [Related]
15. Management of pediatric tumor lysis syndrome.
Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia.
Xue Y; Chen J; Gao S; Zhai X; Wang N; Gao J; Lv Y; Yin M; Zhuang Y; Zhang H; Zhu X; Wu X; Li CK; Hu S; Liang C; Jin R; Jiang H; Yang M; Sun L; Pan K; Cai J; Tang J; Guan X; Fang Y
Sci Rep; 2021 May; 11(1):9656. PubMed ID: 33958615
[TBL] [Abstract][Full Text] [Related]
17. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
18. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Personett HA; Barreto EF; McCullough KB; Dierkhising R; Leung N; Habermann TM
Leuk Lymphoma; 2019 Sep; 60(9):2271-2277. PubMed ID: 31223041
[TBL] [Abstract][Full Text] [Related]
19. Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
L A; Reddy JM; Chebbi PG; Kumar N; Ar AK; M P; B S AK
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3897-3901. PubMed ID: 34967569
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
